JSM 2004 - Toronto

Abstract #300668

This is the preliminary program for the 2004 Joint Statistical Meetings in Toronto, Canada. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2004); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.


Back to main JSM 2004 Program page



Activity Number: 121
Type: Contributed
Date/Time: Monday, August 9, 2004 : 12:00 PM to 1:50 PM
Sponsor: Section on Bayesian Statistical Science
Abstract - #300668
Title: A Bayesian Two-stage Phase II Design with Historical Controls
Author(s): Michael W. Sill*+ and Roger L. Priore
Companies: Roswell Park Cancer Institute and Roswell Park Cancer Institute
Address: GOG Statistical and Data Center, Buffalo, NY, 14263,
Keywords: Bayesian ; design ; phase II ; clinical trials ; sequential ; two-stage
Abstract:

Heitjan (1997) proposed a useful concept called "Bayesian Persuasion Probabilities" for use in phase II clinical trials. Essentially, it involves two competing views of a study agent's effectiveness. Prior to observing the data, the "skeptic" has a tendency to believe in the null hypothesis that a new drug is ineffective while the "enthusiast" has a tendency to believe in the alternative hypothesis (the drug is effective). According to the author, data from a good study should be able to lead both views to the same conclusion. In practice, however, it would take large sample sizes to reach this consensus with high probability. In the proposed design, we will require the data to persuade the enthusiast to abandon the alternative hypothesis and accept the null hypothesis as plausible before a study can close early. On the other hand, the data at the end of the trial must persuade the skeptic to abandon the null hypothesis and accept the alternative as plausible before the design will recommend further study in a phase III trial. This approach seems to yield designs with better operating characteristics for typical phase II sample sizes.


  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2004 program

JSM 2004 For information, contact jsm@amstat.org or phone (888) 231-3473. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2004